Regular use of low-dose aspirin linked to a 20% higher risk of anemia in older adults
An analysis of the ASPREE (Aspirin in Reducing Events in the Elderly) trial found that the use of low-dose aspirin was associated with a 20 percent increased incidence of anemia and a decline in ferritin, or blood iron levels, in otherwise healthy older adults. These findings suggest that periodic monitoring of hemoglobin should be considered in older patients taking aspirin.
Although the risk for over bleeding due to aspirin has been well characterized, very few studies have measured the effect of aspirin on anemia, particularly in older populations.
Researchers from Monash University, Melbourne conducted a post-hoc analysis of the ASPREE randomized controlled trial. The trial included 19,114 persons aged 70 years or older who were randomly assigned to take 100 mg of aspirin daily or placebo. Hemoglobin was measured annually, and ferritin was measured at baseline and 3 years after randomization. The data showed that the risk for developing anemia was 23.5 percent among those assigned to receive low-dose aspirin.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.